Arch Therapeutics Inc (ARTH): Have you ever seen a liquid being classi...

Have you ever seen a liquid being classified

Regis999 · 2019-05-09T20:34:03.4070000Z

Have you ever seen a liquid being classified as a medical device? Well that is what Arch's AC5 is. "Arch's first product stops bleeding in seconds as opposed to competitor products in minutes even in the presence of anticoagulants something that competing products cannot do. Arch's AC5 is A LIQUID noncoagulant homostatic agent classified as a MEDICAL DEVICE." Watch the Roth presentation on Arch's website. https://www.archtherapeutics.com/

Play Episode

5min

Proactive - Interviews for investors

Ilika CEO Graeme Purdy on 50Ah Goliath EV battery prototype milestone; scaling up

Ilika PLC (AIM:IKA, OTCQX:ILIKF) CEO Graeme Purdy joined Proactive's Stephen Gunnion with details about the company's latest milestone—the successful prototyping of its 50Ah Goliath EV battery. This marks a significant leap from the previous 2Ah prototype, representing a 25-fold increase in capacity. Purdy highlighted the importance of scaling up production to meet industry requirements. "We need to make sure that we've got reproducibility. What industry needs is not just a few successful cells but large-scale, reliable production," he said. Ilika has benefited from £2.8 million in grant funding through the Faraday Battery Challenge, which Purdy noted has effectively doubled the impact of investor funding. In parallel, Ilika has also demonstrated its manufacturing process at a giga-scale setting through a partnership with the UK Battery Industrialisation Centre (UKBIC). Looking ahead, the company plans to complete its 1.5MWh per year pilot line with automated equipment. Key upcoming milestones include releasing P1.5 prototypes in the summer and the full P2 release by year-end. Stay tuned for more updates on Ilika’s Goliath program. For more interviews with industry leaders, visit Proactive’s YouTube channel. Don’t forget to like, subscribe, and turn on notifications for future updates. #IlikaPLC #EVBatteries #SolidStateBatteries #BatteryTechnology #EnergyStorage #RenewableEnergy #ElectricVehicles #BatteryInnovation #TechInvesting #ProactiveInvestors

Proactive - Interviews for investors

TNR Gold chair welcomes progress at McEwen Copper's Los Azules copper project in Argentina

TNR Gold Corp (TSX-V:TNR, OTC:TRRXF) executive chairman Kirill Klip talked with Proactive's Stephen Gunnion about the company’s latest developments, including a key milestone in its transition to a cash-flow-generating royalty business. Klip highlighted that TNR Gold holds royalties on significant projects, including the Los Azules Copper project and the Mariana Lithium project in Argentina. With Los Azules now applying for Argentina's incentive regime for large investments, he explained that the project could see substantial tax reductions, making it easier to attract the $2.7 billion investment required for construction. Discussing Argentina’s economic reforms under President Javier Milei, Klip noted that the country's policies are encouraging large-scale investment in the mining sector. He also pointed to the environmental permit secured for Los Azules, bringing it closer to a construction decision, with a feasibility study expected in the first half of the year. Klip also shared insights from Fundamental Research Corporation’s latest analysis, which increased its price target for TNR Gold from $0.24 to $0.28, underscoring the company's transition from a project generator to a cash-flow-generating royalty company. Watch the full interview for more insights into TNR Gold’s latest developments. For more interviews like this, subscribe to Proactive’s YouTube channel, give this video a like, and turn on notifications for future updates! #TNRGold #MiningInvesting #LosAzules #CopperMining #LithiumInvesting #MiningStocks #ArgentinaMining #RoyaltyCompany #StockMarket #JavierMilei

Proactive - Interviews for investors

North Bay Resources ships gold concentrate as mill optimization advances

North Bay Resources has reached a key milestone in its gold production efforts, successfully completing a test shipment of 327 lbs. of gold concentrate from the Bishop Gold Mill to Just Refiners in Reno, NV. CEO Jared Lazerson shared the update with Steve Darling from Proactive, emphasizing the company’s progress in optimizing mill operations and enhancing gold recovery from its Fran Gold Property. The February ore processing runs yielded approximately 2.44 troy ounces of contained gold from 10 tons of ore, equating to a recovered gold grade of 0.24 ounces per ton. Additionally, 0.1 ounces of contained gold remains in low-grade concentrate at the mill. Current estimates place overall recovery at 50%, with gravity-recoverable gold recovery at 70%. Metallurgical testing suggests that up to 67% gravity recovery can be achieved, with an additional 30% recoverable through flotation. To further enhance recovery rates, North Bay Resources is bringing its flotation circuit online, targeting very fine gold and gold in quartz that is not efficiently captured by existing gravity separation methods. This upgrade is expected to boost overall gold recovery by up to 30% as the company continues to refine its extraction process. With ongoing improvements to both its gravity and flotation circuits, North Bay Resources is poised to significantly enhance gold recovery and production efficiency at the Bishop Gold Mill, marking an important step in its broader operational strategy. #proactiveinvestors #northbayresourcesinc #otc #nbri #PlatinumConcentrate #NorthBayResources #MiningNews #CaliforniaGold #JaredLazerson #GoldRush #ProactiveInvestors #PreciousMetals #MiningUpdates ---#invest #investing #investment #investor #stockmarket #stocks #stock #stockmarketnews

Proactive - Interviews for investors

BioHarvest Sciences achieves breakthrough in Liver health with Olive Cell compound

BioHarvest Sciences has announced a significant advancement in liver health research, with new in vitro test results demonstrating the efficacy of its proprietary Olive Cell compound in reducing fat accumulation in human liver cells. CEO Ilan Sobel shared the news with Steve Darling from Proactive, highlighting the compound’s potential in addressing non-alcoholic fatty liver disease (NAFLD)—a condition that affects 30–40% of U.S. adults and currently has limited FDA-approved treatment options. The latest studies revealed that the Olive Cell compound mitigated fat accumulation in both a liver steatosis model and experimental models of liver fibrosis. Additionally, it reduced collagen type 1 levels in XL-2 cells, a key marker of fibrosis progression, further reinforcing its therapeutic potential. BioHarvest attributes these promising results to the compound’s high levels of Verbascoside, a bioactive polyphenol with anti-inflammatory and antioxidant properties. Looking ahead, the company plans to conduct further studies in 2025, with the goal of launching Olive Cell as a nutraceutical product in 2026. Meanwhile, BioHarvest is also exploring pharmaceutical partnerships to bring the compound to market through a CDMO (Contract Development and Manufacturing Organization) model. With these groundbreaking findings, BioHarvest Sciences is positioning itself at the forefront of liver health innovation, offering a potential new solution for millions affected by NAFLD and liver fibrosis. #proactivinvestors #nasdaq #bhst #pharma #biotech #hearthealth #fattyliverdisease #BioHarvestSciences, #IlanSobel, #RevenueGrowth, #NasdaqListing, #IlanSobel #VINIA #HealthTech #Biotech LiverHealth #OliveCell #Verbascoside #NonAlcoholicFattyLiver #SupplementScience #HealthInnovation

Followers	21
Posts	825
Boards Moderated	0
Alias Born	04/10/2005

Volume:	1,335
Day Range:	0.201 - 0.2155
Bid:	0.15
Ask:	0.50
Last Trade Time:	2:44:49 PM EDT
Total Trades:	4

Volume
Day Range:
Bid Price
Ask Price
Last Trade Time:

Boards:

Quotes:

Boards

News

Market Data

Markets

Discover

Discover

Boards:

Quotes:

ARTH Detailed Quote

Recent ARTH News

More ARTH News

Boards:

Quotes:

Boards

News

Market Data

Markets

Discover

Discover

Boards:

Quotes:

Recent ARTH News

Go Ad-Free